Blood Cancer Journal
IF
8.02
Papers
947
Papers 1162
1 page of 117 pages (1,162 results)
Newest
#1Srikanth Talluri (Harvard University)H-Index: 10
#2Mehmet Kemal Samur (Harvard University)H-Index: 24
Last. Nikhil C. Munshi (Harvard University)H-Index: 147
view all 9 authors...
Multiple myeloma (MM) is a heterogeneous disease characterized by significant genomic instability. Recently, a causal role for the AID/APOBEC deaminases in inducing somatic mutations in myeloma has been reported. We have identified APOBEC/AID as a prominent mutational signature at diagnosis with further increase at relapse in MM. In this study, we identified upregulation of several members of APOBEC3 family (A3A, A3B, A3C, and A3G) with A3G, as one of the most expressed APOBECs. We investigated ...
Source
#1Hiroto Ohguchi (Harvard University)H-Index: 16
#2Teru Hideshima (Harvard University)H-Index: 133
Last. Kenneth C. Anderson (Harvard University)H-Index: 5
view all 3 authors...
Source
#1Christina Rautenberg (HHU: University of Düsseldorf)H-Index: 9
#2Friedrich Stölzel (TUD: Dresden University of Technology)H-Index: 25
Last. Felicitas Thol (MHH: Hannover Medical School)H-Index: 45
view all 49 authors...
To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was 47% including 64% of patients with available informat...
Source
VIALE-C compared the safety and efficacy of venetoclax or placebo plus low-dose cytarabine (+LDAC) in patients with untreated AML ineligible for intensive chemotherapy. Overall, 211 patients were enrolled (n = 143, venetoclax; n = 68, placebo). At the primary analysis, the study did not meet its primary endpoint of a statistically significant improvement in overall survival (OS), however, ~60% of patients had been on study for ≤6-months. Here, we present an additional 6-months of follow-up of VI...
Source
#1Ghayas C. Issa (University of Texas MD Anderson Cancer Center)H-Index: 11
#2Jabra Zarka (University of Pittsburgh)
Last. Keyur P. Patel (University of Texas MD Anderson Cancer Center)H-Index: 37
view all 21 authors...
Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various translocations causing KMT2Ar are conflicting. Less is known about associated mutations and their prognostic impact. In a retrospective analysis, we identified 172 adult patients with KMT2Ar AML and compared them to 522 age-matched patients with diploid AML. KMT2Ar AML had fewer mutations, most commonly affecting RAS and FLT3 ...
Source
#1Radhika Bansal (Mayo Clinic)
#2Sagar Rakshit (Mayo Clinic)H-Index: 8
Last. Shaji Kumar (Mayo Clinic)H-Index: 123
view all 3 authors...
When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective. The pathogenetic mechanisms are not completely understood and it is generally associated with high-risk cytogenetics which portends poor outcomes. There is a rising incidence of EMD in the era of novel agents, lik...
Source
#1Sanjal Desai (Mayo Clinic)
#2Betsy LaPlant (Mayo Clinic)H-Index: 43
Last. Stephen M. Ansell (Mayo Clinic)H-Index: 99
view all 13 authors...
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of MC078E, a phase II clinical trial testing lenalidomide plus R-CHOP (R2CHOP) for patients with untreated transformed/concurrent DLBCL (NCT00670358). Adult patients with transformed or concurrent DLBCL were included. Patients received six cycles of rit...
Source
#1Shuhei Kurosawa (UTokyo: University of Tokyo)H-Index: 7
#2Shohei Mizuno (Aichi Medical University)H-Index: 10
Last. Yuta KatayamaH-Index: 10
view all 19 authors...
The present study evaluated outcomes and prognostic factors in adult patients with acute myeloid leukemia (AML) after syngeneic hematopoietic stem cell transplantation (HSCT). Among patients in first complete remission (CR1), outcomes of syngeneic HSCT (Syn) were compared with those of autologous HSCT (Auto), allogeneic HSCT from human leukocyte antigen (HLA)-matched sibling donor (MSD), or allogeneic HSCT from HLA-matched unrelated donor (MUD). Among 11,866 patients receiving first HSCT, 26 in ...
Source
#1Matthew Ho (Mayo Clinic)H-Index: 16
#2Saurabh Zanwar (Mayo Clinic)H-Index: 8
Last. Eli Muchtar (Mayo Clinic)H-Index: 21
view all 19 authors...
The optimal duration of lenalidomide maintenance post-autologous stem cell transplant (ASCT) in Multiple Myeloma (MM), and choice of therapy at relapse post-maintenance, need further evaluation. This retrospective study assessed outcomes of patients with MM (n = 213) seen at Mayo Clinic, Rochester between 1/1/2005-12/31/2016 who received lenalidomide maintenance post-ASCT. The median PFS was 4 (95% CI: 3.4, 4.5) years from diagnosis of MM; median OS was not reached (5-year OS: 77%). Excluding pa...
Source
#1Nora E. Rahmani (Albert Einstein College of Medicine)
#2Nandini Ramachandra (Albert Einstein College of Medicine)H-Index: 5
Last. Mohammad Kazemi (Albert Einstein College of Medicine)H-Index: 1
view all 30 authors...
The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1G710X mutation showed reduced leukemic growth, increased myeloid differenti...
Source
12345678910
Top fields of study
Oncology
Hematology
Immunology
Multiple myeloma
Leukemia
Cancer research
Medicine